Age-related Macular Degeneration
Age-related macular degeneration stands as the leading cause of vision loss among older adults in the United States. This progressive eye condition affects the macula, the central part of the retina responsible for sharp vision needed for activities such as reading and driving.
Age-related macular degeneration manifests in two primary forms: Dry Macular Degeneration and Wet Macular Degeneration. Dry Macular Degeneration, the more common form, typically progresses slowly and involves the breakdown of light-sensitive cells in the macula, leading to a gradual loss of central vision. On the other hand, Wet Macular Degeneration, while less common, progresses more rapidly and is characterized by the growth of abnormal blood vessels beneath the retina, which leak fluid and blood, causing sudden and severe vision loss.
Fortunately, advancements in medicine have brought about treatments for both forms of macular degeneration. In the case Wet Macular Degeneration, the treatments aim to halt the growth of abnormal blood vessels and prevent further vision loss. This goal is achieved via injection of medication into the eye under sterile environment by a retina specialist and at specific intervals. The delivery of medicine into the eye inhibits further progression of disorder and in many cases even leads to regression of abnormal blood vessels and visual improvement.
Recently, a new class of medication have been introduced to halt progression of advance forms of Dry Macular Degeneration. Though, these medications are relatively new, their emergence has sparked a glimmer of hope in management of Dry Macular Degeneration.
At New England Retina Care, we take pride in offering a comprehensive range of latest treatments available for Age-related Macular Degeneration. We work with our patients to find the most suitable treatment options, adjusting therapies to match each individual circumstance and to obtain the best visual outcome.
Please contact us for further information or to schedule a consultation.